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Vaginal metabolome: towards a 
minimally invasive diagnosis of 
microbial invasion of the amniotic 
cavity in women with preterm labor
Sara Vicente-Muñoz1, teresa cobo2,3*, Leonor puchades-carrasco4,5, Ana B. Sánchez-García2, 
núria Agustí2, Montse palacio2,3, Antonio pineda-Lucena4,5,6,7 & eduard Gratacós2,3
Microbial invasion of the amniotic cavity (MIAC) is only identified by amniocentesis, an invasive 
procedure that limits its clinical translation. Here, we aimed to evaluate whether the vaginal 
metabolome discriminates the presence/absence of MiAc in women with preterm labor (ptL) and 
intact membranes. We conducted a case-control study in women with symptoms of PTL below 34 
weeks who underwent amniocentesis to discard MIAC. MIAC was defined as amniotic fluid positive for 
microorganisms identified by specific culture media. The cohort included 16 women with MIAC and 
16 control (no MIAC). Both groups were matched for age and gestational age at admission. Vaginal 
fluid samples were collected shortly after amniocentesis. Metabolic profiles were analyzed by nuclear 
magnetic resonance (nMR) spectroscopy and compared using multivariate and univariate statistical 
analyses to identify significant differences between the two groups. The vaginal metabolomics profile of 
MiAc showed higher concentrations of hypoxanthine, proline, choline and acetylcholine and decreased 
concentrations of phenylalanine, glutamine, isoleucine, leucine and glycerophosphocholine. in 
conclusion, metabolic changes in the NMR-based vaginal metabolic profile are able to discriminate the 
presence/absence of MiAc in women with ptL and intact membranes. these metabolic changes might 
be indicative of enhanced glycolysis triggered by hypoxia conditions as a consequence of bacterial 
infection, thus explaining the utilization of alternative energy sources in an attempt to replenish 
glucose.
Maternal and fetal medicine is moving toward individualized patient-care aiming to identify the most appro-
priate clinical management for each woman. In women with preterm labor (PTL), early spontaneous preterm 
deliveries (PTD) are more likely related to microbial invasion of the amniotic cavity (MIAC) and intra-amniotic 
inflammation (IAI)1. Diagnosis of MIAC help clinicians to identify women with high-risk of delivering in the fol-
lowing days2. This information may be used to efficiently plan antenatal management3 by transfer to facilities with 
Neonatal Intensive Care Units (NICU), administration of antenatal steroids4, magnesium sulfate5 and, probably, 
with specific antibiotics6 according to the microorganism isolated. Furthermore, additional information about 
MIAC may not only render antenatal strategies, such as tocolysis, questionable, but may also help neonatologists 
improve neonatal management.
Nowadays, amniocentesis is the only procedure to identify MIAC since it can occur without a clinical sus-
picion. Despite the very low rate of complications associated with amniocentesis7, the invasive nature of this 
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procedure limits its clinical translation. This limitation has led to exploring the intra-amniotic environment using 
minimally invasive strategies based on the analysis of different biofluids, including vaginal fluid8.
In this context, high-dimensional biology referred to as “omics” provide a comprehensive description of the 
biological processes and has facilitated better understanding of the biochemical changes associated with complex 
diseases, and is able to identify biomarkers and advance in translational research. Metabolomics appears to be 
one of the most promising approaches in maternal and fetal medicine to study the complex interactions between 
mother, placenta, and fetus9. It allows simultaneous examination and relative quantification of changes in the 
metabolome, which is the final downstream product of all the biochemical processes and more closely reflects the 
phenotype at a functional level. Furthermore, metabolomics allows the understanding of the molecular mech-
anisms responsible for the deregulation and provides a logical strategy for intervening in the process10. Nuclear 
Magnetic resonance (NMR) spectroscopy is a profiling technology that provides highly reproducible information 
on complex biological fluids or tissues, with minimal preparation and in an essentially non-destructive manner.
Several metabolomic studies have monitored healthy pregnancy11,12. Other reports have mainly focused on 
selected stages or disorders of pregnancy, such as fetal malformations13, gestational diabetes mellitus14, preec-
lampsia15, neural tube defects16, very-low birth weight17, fetal lung maturity18 and PTD19–25. Regarding MIAC 
or IAI, Romero et al.20 found differences in the amniotic fluid metabolome in women with symptoms of PTL 
according to information of MIAC. Brown et al.26 observed changes in the metabolic profiles of amniotic fluid, 
fetal brain and postnatal brain of pregnant mice exposed to IAI. However, to our knowledge, there are no data on 
the metabolome profile of women with PTL to diagnose MIAC using a minimally invasive approach.
This study describes an untargeted 1H-NMR metabolomics approach, based on the analysis of vaginal fluid to 
identify metabolic profiles associated with MIAC. The characterization of this minimally invasive biofluid pro-
vides information on the metabolic networks directly related to the presence of an ascending bacterial infection 
in the amniotic fluid and to explore the effect of the process through vaginal fluid. In addition, identification of 
a vaginal metabolic profile of MIAC in women with PTL and intact membranes. could help clinicians to target 
women who might benefit from amniocentesis for this indication. Therefore, the main objective of this study 
was to characterize the vaginal metabolome profile of MIAC in women with PTL presenting intact membranes.
Results
This case-control study included 32 women, 16 in each group. Maternal clinical characteristics and demo-
graphic details of the women included in the study are summarized in Table 1. All women with PTL had intact 
membranes.
Sixteen women had MIAC. The microorganisms most frequently isolated in the amniotic fluid were 
Ureaplasma spp. (n = 5) and Fusobacterium nucleatum (n = 5). Other microorganisms isolated were Listeria 
monocytogenes (n = 1), Streptococcus viridans (n = 1), Capnocytophaga sputigena (n = 1), Escherichia coli (n = 1) 
and Candida albicans (n = 2). We did not find differences in the rate of positive vaginal cultures or in the antenatal 
management (e.g., antenatal steroids, tocolysis or antibiotics administration prior to vaginal sampling) between 
groups.
1H-NMR metabolic profile of vaginal samples. 1H-NMR CPMG spectra were acquired for all the vag-
inal samples included in the study. Figure 1 shows a representative 1H-NMR vaginal spectrum from a woman 
with MIAC. A total of 34 metabolites were assigned in the region between 0.5 and 8.5 ppm, including amino 
acids (e.g., leucine, valine, alanine, threonine, glutamine, phenylalanine), organic acids (e.g. lactate, fumarate, 
formate), energy-related metabolites, sugars and lipids. Direct analysis by NMR was not possible due to extremely 
high viscosity of the vaginal fluid and therefore this biofluid was lyophilized and consequently reconstituted in 
100% D2O. The quality of the spectra and signal-to-noise ratio obtained proved to be a robust method to analyze 
vaginal samples by NMR.
Multivariate statistical analysis and group discrimination. For identifying the differences between 
both groups, multivariate statistical analysis was applied to all the samples included in the study. First, a 
non-supervised analysis on vaginal fluid 1H-NMR spectra was performed for identifying intra- and inter-groups 
variability. A PCA was carried out to evaluate sample homogeneity within each group of samples and examine 
the potential influence of different clinical variables (i.e., gestational age at admission, days between admission 
and delivery) in the overall distribution of the data. PCA analysis did not reveal any pattern or clustering of the 
samples according to different clinical variables (i.e., gestational age at admission, days between admission and 
delivery) (data not shown). However, this analysis did not reveal either any pattern or clustering of the samples 
according to these descriptors; thus, it was possible to discard these variables as potential confounding factors. 
Furthermore, dilution differences were identified between vaginal samples, probably derived from the method of 
sample collection. This variability in sample concentration did not correlate with respond clinical variable or con-
dition, probably reflecting inter-individual variability in vaginal fluid concentration. This effect was compensated 
using PQN normalization in vaginal samples.
Next, OPLS-DA method was applied, as method of classification, to compare the two groups of patients 
included in the study and identify the differences associated with these clinical situations. The samples were clas-
sified as positive (+AF) or negative (−AF) based of the presence or absence of MIAC, respectively. The score plot 
showed a clear separation between vaginal samples collected from women with and without MIAC (R2Y = 0.525 
and Q2 = 0.296) (data not shown).
To select the most relevant variables contributing to the discrimination of the women with and without MIAC, 
variable selection was performed using the ratio between regression coefficients values and the Jack-knife stand-
ard error of their coefficients (CoeffCS/CoeffCScvSE). These ratio values were used to select those variables, 
which mainly contribute to the separation between both groups of samples. Applying this strategy, only those 
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variables with a ratio larger than 1 were maintained and used to build the new OPLS-DA model. The rest of the 
descriptors were excluded as they were deemed uninformative variables with low or null discrimination abil-
ity in the model; therefore, not correlated with biological differences associated with the disease. After variable 
selection, a new OPLS-DA model (Fig. 2A) was built with the subset of selected variables. In the new model both 
goodness of fit and prediction were improved (R2Y = 0.535 and Q2 = 0.405) exhibiting a clear separation between 
the two groups of samples. The quality of the OPLS-DA obtained was validated with a permutation test. After one 
hundred class permutations (Fig. 2B) the validation plot presented R2 and Q2-intercept values were significantly 




Control (n = 16) p. value
Maternal age 33.4 (24.2; 37.6) 31.8 (27.0; 35.7) 0.386
Caucasian ethnicity 16 (100) 15 (93.8) 1.000
Nulliparity 8 (50) 8 (50) 1.000
Prior PTD 4 (25) 3 (18.8) 1.000
CRP (mg/L) at admission 3.8 (0.8;7) 0.6 (0.3; 1.3) 0.002
WBC (x109/L) at admission 12280 (10077; 16652) 12635 (9832; 14600) 0.546
US CL (mm) at admission 3 (0; 25) 15 (8; 23) 0.097
Positive genital cultures at admission 8 (50) 3 (18.8) 0.135
GA at sampling (weeks) 25.0 (22.3; 30.3) 26.9 (26.3; 30.8) 0.169
AF glucose (mg/d) 4 (1.2; 14) 33.5 (24.2; 38.7) <0.0001
Steroid administration 13 (81.2) 15 (93.8) 0.600
Antibiotic treatment 16 (100) 5 (31.2) <0.0001
Antibiotic treatment prior to vaginal 
sampling (days) 0 (0; 0) 0 (−0.5; 30.5) 0.839
Tocolysis treatment 14 (87.5) 15 (93.8) 1.000
GA at delivery (weeks) 26.3 (25.1; 30.5) 37.1 (34.1; 39.9) <0.0001
Latency from sampling to delivery (days) 2.5 (1; 5.7) 63 (40.2; 79.7) <0.0001
Birth weight (g) 870 (667.5; 1363.7) 2894 (1985; 3407.5) <0.0001
Male gender 6 (37.5) 7 (43.8) 1.000
Table 1. Maternal characteristics and perinatal outcome. MIAC: Microbial invasion of the amniotic cavity; 
PTD: Preterm delivery; CRP: C-reactive protein; WBC: White blood cells; US CL: Ultrasound cervical length; 
GA: Gestational age; AF: Amniotic fluid. Continuous variables were compared using a nonparametric Mann-
Whitney U test presented as medians (25th; 75th percentile). Categorical variables were compared using Chi-
square or Fisher exact test and presented as number (%). p value < 0.05 was considered statistically significant.
Figure 1. Representative 600-MHz 1H-NMR spectrum of a vaginal fluid sample from a woman with presence 
of MIAC. (A) Full spectrum (δ 8.5–0.5 ppm); (B) Magnification of the spectrum region from δ 5.6–8.4 ppm.
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Characterization and quantification of the infection metabolic profile. Multivariate data analysis 
facilitated the identification of variables responsible for the separation between the two groups. Each relevant 
region, in terms of VIP values, was subsequently evaluated individually. Thus, a total of 52 buckets with VIP value 
>1 were obtained based on the analysis of the final OPLS-DA model. These spectral regions were considered very 
relevant variables in the separation between the two groups (No-MIAC vs. MIAC).
Univariate statistical analysis of the previously selected spectral regions revealed significant differences 
(p-value < 0.05) between the two groups. The levels of four metabolites were found to be significantly higher 
in the vaginal fluid from women with MIAC (hypoxanthine (85.90%), proline (88.83%), choline (71.56%) and 
acetylcholine (30.96%)), and five metabolite levels were lower as compared to control women (phenylalanine 
(−35.14%), glutamine (−29.66%), leucine (−33.69%), isoleucine (−27.63%) and glycerophosphocholine 
(−32.85%)) (Table 2). Benjamini-Hochberg adjusted p-values are shown in Supplementary Table 1.
Discussion
Our preliminary data, derived from the analysis of metabolite profiles using multivariate and univariate statistical 
methods, revealed that the vaginal metabolic profile of women with PTL and intact membranes discriminates 
between women with and without MIAC.
Previous studies have shown vaginal metabolome profile related to the occurrence of bacterial vaginosis (BV) 
and other clinical outcomes such as PTD. Thus, an untargeted metabolomics analysis of vaginal fluid identified 
biomarkers associated with BV and validated the results in a blinded replication cohort27 with 91% accuracy. 
A recent study reported the metabolic profile of women with and without BV using mass spectrometry-based 
metabolomics and classified women based on their vaginal metabolite composition28. Amabebe et al.29 
Figure 2. Multivariate Statistical model resulting from the analysis of 1H-CPMG spectra for the comparison 
between control individual (red) vs. women with MIAC (black) and the corresponding internal cross-validation 
test. (A) OPLS-DA score plot calculated after variable selection (R2Y(cum): 0.535; Q2(cum): 0.405) showing the 
separation between both groups of samples. (B) Permutation test (n = 100) obtained from the corresponding 
PLS-DA model with an equivalent number of components used for the OPLS-DA model with values of 
intercepts R2: 0.402 and Q2: −0.197.
δ 1H (ppm)a Metabolite(s) p. valueb % Variationc
8.1845–8.1715 Hypoxanthine 0.001 85.90
7.3845–7.3425 Phenylalanine 0.032 −35.14
3.3405–3.3315 Proline 0.003 88.83
3.2135–3.2045 Glycerophosphocholine 0.007 −32.85
3.2035–3.1955 Acetylcholine 0.042 30.96
3.1945–3.1795 Choline 0.007 71.56
2.3515–2.3105 Glutamine 0.004 −29.66
1.0035–0.9914 Isoleucine 0.046 −27.63
0.9604–0.9374 Leucine 0.035 −33.69
Table 2. Variations for the statistically significant metabolites involved in the discrimination between women 
with MIAC (n = 16) and without (n = 16). aChemical shift range for the integration; bp. value calculated by 
Wilcoxon-Mann-Whitney U test; crelative variation of the metabolite levels in women with MIAC compared 
with women without MIAC.
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hypothesized that the cervicovaginal ecosystem of commensal and pathogenic organisms could induce a specific 
metabolic profile that could be used for predicting the risk of PTD. In agreement with their previous report29, they 
demonstrated the potential of cervicovaginal acetate levels as a predictor of PTD using 1H-NMR spectroscopy, 
especially in women with symptoms of PTL30.
Our study focused on the characterization of the vaginal metabolome of women with MIAC. The majority of 
MIAC have an ascending origin31. Vaginal secretions from the women recruited in this study exhibited specific 
metabolite changes associated with infection. Their vaginal metabolic profile showed decreased concentrations of 
amino acids (phenylalanine, glutamine), branched-chain amino acids (leucine, isoleucine), and glycerophospho-
choline as well as increased hypoxanthine, proline, choline and acetylcholine concentrations (Table 2).
It is known that bacterial pathogens trigger a specific host response characterized by: (a) the induction of host 
cell enzymes, which dampens the production or action of reactive oxygen species (ROS) and reactive nitrogen 
intermediates, (b) a further enhanced glucose uptake and glycolysis which stimulate the anabolic activity of the 
host cells (e.g., by increased production of nucleotides and amino acids), and (c) a switch to enhance glutaminol-
ysis and citrate lyase reaction reinforcing fatty acid/lipid biosynthesis32.
One of the most significant differences is associated with the levels of free choline, being much higher in 
vaginal samples from women with MIAC. During gestation, there is a high demand for this essential nutrient33. 
Large amounts of choline are delivered to the fetus across the placenta34. Choline is closely associated with fetal 
brain development and has also been shown to change in relation to hypoxia and pre-eclampsia35,36. Werth and 
co-workers demonstrated that hypoxia inducible transcription factor-1 (HIF-1) activation in infections with 
human pathogenic microorganisms is a general phenomenon37. Therefore, it would likely explain the increased 
levels of choline observed, as well as those from its downstream product acetylcholine. Hypoxanthine, an ATP 
degradation product under hypoxic conditions36 has been defined as biomarkers of hypoxia, hypoxemia and 
ischemic brain injury38. Elevation of hypoxanthine has also been reported during septic shock and may reflect 
early high energy nucleotide failure39. Moreover, circulating hypoxanthine levels have been found to increase dur-
ing the febrile phase40, as well as in models of chronic systemic inflammation40. Based on these previous findings, 
it is feasible that similar events could be observed in infectious diseases in which acute bouts of inflammation 
occur, such as in MIAC.
The vaginal profile of women with MIAC exhibits a profound disturbance in amino acid metabolism that 
is characterized by decreased levels of phenylalanine, isoleucine, glutamine and leucine. This finding could be 
consistent with an increased glycolysis induced by hypoxic conditions, thus explaining the utilization of selected 
amino acids as an alternative energy source for the replenishing of glucose41. To this end, it is important to point 
out that short peptides are usually taken by microorganisms, for optimal growth during infection, and degraded 
into amino acids, that are eventually catabolized for replenishing TCA cycle intermediates and generating gluco-
neogenic substrates42.
Taken together, the vaginal metabolic profile observed in women with MIAC seems to reflect the interplay 
between microorganisms and host and involves a large variety of physiological responses. One of the strengths 
of the study is the well-characterized study population with information of MIAC, the accurate sampling pro-
cessing and the close perinatal follow-up. Some of the limitations of this study refer to the method used for 
detecting MIAC, we did not perform genomic non-cultivation technology analyses. However, to date, amni-
otic fluid cultures continue to be the “gold standard” to define MIAC in most clinical settings. Furthermore, we 
acknowledge the small number of samples available from MIAC women presenting PTL and intact membranes. 
These preliminary data require to be validated in a larger cohort to ensure reproducibility; special efforts will be 
paid to the collection of an independent validation cohort. Finally, we did not characterize vaginal microbiota 
in these women being therefore unable to investigate the relation between vaginal microbiota and metabolome 
expression in women with MIAC. In this regard, some studies have shown how vaginal microbiome modulates 
metabolome expression in women with genital infections43–45. Future studies evaluating the association between 
vaginal microbiota, metabolomic profiles and perinatal outcomes, such as spontaneous preterm birth, in women 
with MIAC are warranted.
In conclusion, a specific vaginal metabolome profile of MIAC was characterized in women with PTL and 
intact membranes. The results of this study open the possibility to target women with a high-risk of MIAC using 
minimally invasive sampling method, thereby limiting amniocentesis in this high-risk group. In addition, pend-
ing validation, this experimental setup could be expanded to the evaluation and monitoring of the infectious 
process and, eventually, the response to specific therapies in women with MIAC.
Materials and Methods
Study design and subject recruitment. This study was conducted as a case-control study and included a 
group of 32 women with symptoms of PTL and intact membranes admitted to the Maternal and Fetal Medicine 
Department of Hospital Clinic, Barcelona, under 34 weeks of gestation with an amniocentesis to discard MIAC. 
Both groups were matched for age and gestational age at admission. Clinical diagnosis and classification of 
women was performed according to the presence/absence of MIAC. Exclusion criteria were clinical signs of 
chorioamnionitis, multiple gestation, preterm prelabor rupture of membranes, fetuses with aneuploidy, mater-
nal diabetes, women who did not consent to participate in the study, and cases in which amniocentesis was not 
technically possible.
Gestational age was established according to the first-trimester ultrasound scan. PTL was defined as the pres-
ence of regular uterine contractions with a frequency of at least 2 every 10 minutes and an ultrasound cervical 
length below the 5th percentile for gestational age46. MIAC was defined as a positive aerobic/anaerobic amniotic 
fluid culture for bacteria or yeast or the presence of Ureaplasma spp. or Mycoplasma hominis in genital myco-
plasma culture.
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Study population recruitment and sample collection were carried out at the Materno-fetal Medicine 
Department of Hospital Clinic, Barcelona (Spain) from 2010 to 2013. NMR spectra acquisition and the metabo-
lomics analysis were performed at Centro de Investigación Príncipe Felipe, Valencia (Spain).
ethical approval. Recruitment and sampling procedures were performed in accordance with the Declaration 
of Helsinki and applicable local regulatory requirements after approval from the Ethics Committee of the Hospital 
Clinic of Barcelona (HCB/2010/5811). Written informed consent was obtained from all the subjects included in 
this study.
clinical management. The antenatal management of women with PTL has been reported previously47 and 
includes fetal maturation with a complete course of antenatal steroids (betamethasone) between 24.0 to 34.6 
weeks and tocolysis (nifedipine or atosiban). Antibiotics (ampicillin, gentamycin, azithromycin) were prophy-
lactically initiated in women with advanced cervical dilatation (Bishop index >6) and were discontinued if the 
amniotic fluid culture result was negative. Women with amniotic fluid glucose levels <5 mg/dL and/or with 
microorganisms on Gram staining and/or positive amniotic fluid cultures were treated with antibiotics according 
to the antibiogram of microorganisms isolated.
Amniotic and vaginal fluid collection. Amniotic fluid samples were obtained by transabdominal amni-
ocentesis at admission. Cultures for genital mycoplasma (Mycoplasma IST 2, bioMérieux for Ureaplasma spp. 
or Mycoplasma hominis), aerobic (Chocolate agar), anaerobic (Schaedler agar for anaerobes and thioglycollate 
broth) bacteria, as well as amniotic fluid glucose concentrations and Gram stains were performed immediately 
after the procedure and the results were available for clinical decisions.
Vaginal fluid samples were collected using Cytobrush swabs (Cytobrush Plus GT; Medscan Medical AB) from 
the posterior vaginal fornix shortly or within 24–48 h after amniocentesis sampling. Each Cytobrush was sub-
merged in 1.0 mL of sodium chloride (NaCl) (9 mg/mL) and kept at 4 °C until processing. Vaginal fluid was cen-
trifuged at 3421 g at 4 °C for 10 minutes and supernatant was stored at −80 °C until the NMR analysis.
nMR sample preparation. Vaginal fluid samples were thawed on ice and gently mixed before sample 
preparation. 500 µL of freeze-dried vaginal fluid sample were dissolved in 500 µL of D2O containing 1 mM of 
trimethylsilylpropionic acid-d4 sodium salt (TSP) as internal standard compound48,49, and 60 µL of 1.5 M potas-
sium phosphate buffer (pH 7.4) in D2O. The mixture was transferred to a 5-mm and stored at 4 °C until analysis.
1H-NMR Spectroscopy of vaginal fluid. NMR data acquisition. NMR spectra were acquired using a 
Bruker Avance II 600 MHz spectrometer (Bruker Biospin, Rheinstetten, Germany) equipped with a triple res-
onance cryo-probe with a cooled 13C preamplifier (TCI). 1H-NMR experiments were acquired at 310 K using 
a standard Carr-Purcell-Meiboom-Gill (CPMG) spin-echo pulse sequence50, which generates spectra edited 
with reduced broad resonances from high molecular weight improving the resolution of low molecular weight 
metabolites resonances. For each sample, 128 transients were collected into 74 K data points using a spectral 
width of 20 ppm. Water resonance was presaturated with a 25-Hz pulse during a 4-second relaxation delay. Free 
induction decays were multiplied by an exponential function equivalent to a 1.0 Hz line-broadening factor before 
applying Fourier transformation. Additionally, 2D 1H-1H TOtal Correlation SpectroscopY (TOCSY) and 2D 
1H, 13C Heteronuclear Single Quantum Correlation (HSQC) experiments were performed for selected samples, 
to facilitate the identification of biochemical substances. Most of the metabolites were assigned comparing vag-
inal profiles with compounds included in the BBIOCODEREF library (Bruker BioSpin) on Analysis of Mixture 
software (v. 3.9.7; Bruker BioSpin). This information was complemented with other existing public databases 
HMDB (Human Metabolome database) and BMRB (Biological Magnetic Resonance Data Bank) and literature 
reports51,52.
Spectral data processing. All transformed 1D 1H-CPMG spectra were phased and baseline corrected auto-
matically using TopSpin (v 2.1, Bruker BioSpin, Rheinstetten, Germany). Spectra were internally calibrated with 
reference to the CH3 alanine peak at 1.47 ppm. For spectral data reduction, each vaginal spectrum (δ 0.60–8.46) 
was segmented into consecutive equal width buckets (0.04 ppm) using AMIX software (v 3.9.7; Bruker BioSpin). 
After excluding residual water signal (δ 4.41–4.87) and baseline regions, the spectra were normalized by probabil-
istic quotient normalization (PQN)53 to compensate dilution differences in sample concentration.
Multivariate statistical analysis. Analysis of metabolite profiles was carried out using SIMCA-P software 
(v.13.0.2, Umetrics). Prior to this analysis, data were scaled to unit variance (UV) scaling, where the variable is 
centered and scaled by dividing by its standard deviation, giving all of the variables equal importance. First, unsu-
pervised principal component analysis (PCA) was performed for finding potential patterns, intrinsic clusters and 
outliers. Next, orthogonal partial least square to latent discriminant analysis (OPLS-DA), a supervised method, 
was applied for maximizing class discrimination and minimizing the possible contribution of intragroup variabil-
ity. The OPLS-DA model was assessed by R2Y (quantitative measure of goodness of fit) and Q2 (predictive ability 
calculated by 7-fold internal cross-validation rounds) parameters.
The initial OPLS-DA model was improved using variable selection to identify the relevant predictors and to 
exclude uninformative variables. The centered and scaled regression coefficients (CoeffCS) and their Jack-knife 
standard error of the coefficients (CoeffCScvSE) computed from all rounds of cross validations were used to 
discard spectral regions that were redundant or not correlated to the response54. With this strategy, only those 
variables, with a ratio between CoeffCS and CoeffCScvSE >1, were included in the model. Once applied, the vari-
able selection method, a new OPLS-DA model, was calculated and internal cross validation and permutation tests 
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were performed to evaluate the model obtained. Variables or spectral regions (buckets) with variable importance 
in the projection (VIP) scores larger than 1 from the 7-fold cross validated OPLS-DA model were considered 
responsible for the discrimination between both groups and were evaluated individually by univariate statistical 
analysis as potential biomarkers.
Permutation tests (n = 100) were carried out using SIMCA-P software (version 13.0.2, Umetrics), as internal 
validation method, for the evaluation of the quality of the OPLS-DA obtained. The class label of each sample was 
randomly permuted, and R2Y and Q2 values obtained from the permutated models were compared with the R2Y 
and Q2 values from the original model.
Univariate statistical analysis and metabolite quantification. Relevant spectral regions responsible 
for the discrimination between the two groups, as derived from the multivariate OPLS-DA models, were selected 
and evaluated independently. The relative concentration of each metabolite was calculated by integrating the 
signals in the spectra. For continuous variables statistical significance was assessed using the non-parametric 
Wilcoxon-Mann-Whitney U test, metabolites with a p. value < 0.05 were considered significantly different. 
Chi-square test was applied for categorical variables. A p. value < 0.05 with two-sided alternative hypotheses 
were considered statistically significant. Benjamini-Hochberg correction was performed to control the false dis-
covery rate55.
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